![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Purpose: To evaluate outcomes of long-term follow-up of Retisert multiple implantation and dissociation in eyes with chronic noninfectious uveitis.
Methods: Review of 187 consecutive Retisert implants. Outcomes of multiple implantation and spontaneous medication pellet-strut dissociation were evaluated.
Results: A total of 187 consecutive Retisert implants were reviewed. Eight implants were removed. The prevalence of spontaneous dissociation was 2.6% (5/187). The rate of dissociation increased to 11.11% (2/18) in cases of multiple implants. The mean period between Retisert implantation and spontaneous dissociation was 65.05 months. The mean period between implants in the same eye was 55.25 months. In cases of multiple implantations the old implant was not removed and 17.64% (3/17) of eyes required glaucoma filtering surgery.
Conclusion: The rate of spontaneous dissociation of Retisert medication pellet-strut in eyes with single implant for noninfectious uveitis is low, which tends to increase in eyes with multiple implants.
Declaration of interest
No funding or support was received for this study. The authors have no financial interest in the products mentioned in this manuscript. Dr. Foster reported have been a consultant for Abbvie, Alcon Laboratories, Allergan, Ista Pharmaceuticals, LUX Biosciences, Novartis Pharmaceuticals, and Bausch & Lomb Surgical; having received grants or having pending from Abbvie, Alcon Laboratories, Allergan, Eyegate, LUX Biosciences, Novartis Pharmaceuticals, pSivida, Sanofi-Aventis, XOMA, and Santen; Having received honorari for lectures including service on speakers bureaus for Alcon Laboratories, Allergan, Inspire, Ista Pharmaceuticals, and LUX Bioscience; and having stock or stock options in Eyegate. No other disclosures were reported.